• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

    2.960 -0.120 (-3.90%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 126,537
    Open 3.020
    Bid (Size) 2.930 (1)
    Ask (Size) 3.130 (6)
    Prev. Close 3.080
    Today's Range 2.910 - 3.140
    52wk Range 2.130 - 20.71
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
    SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire

    Performance

    YTD
    -44.47%
    -44.47%
    1 Month
    +2.07%
    +2.07%
    3 Month
    -41.04%
    -41.04%
    6 Month
    -51.07%
    -51.07%
    1 Year
    -75.04%
    -75.04%

    More News

    Read More
    Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    What's Going On With Sagimet Biosciences Stock On Thursday?
    Via Benzinga
    Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
    Via Benzinga
    Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024
    Via InvestorPlace
    Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Via The Motley Fool
    Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.